Building Biotechs · 2024-11-08 · 38 min
This week, I spoke with Natalie Nairn, co-founder and CEO of Cyclera Therapeutics. Natalie is also a Termeer Fellow, and listeners of this podcast know how much I love the Termeer Foundation. We discuss her transition from chemical engineering to biomedical applications. She describes her unexpected path into the fun and volatile startup space, which led to her founding Cyclera. Natalie explains the importance of focusing in biotech development, the promising applications of Cyclera's technology in CNS therapeutics, and the challenges and opportunities in the current funding landscape. She also highlights the value of the Termeer fellowship in her career, the contrast between Boston and Seattle's biotech scenes, and the essential aspects of leadership and team cohesion. Finally, Natalie discusses her future goals for Cyclera and offers valuable advice for aspiring biotech founders. Get Natalie's recommended book! The Book of Delights: Essays CYpHER: catalytic extracellular targeted protein degradation with high potency and durable effect | Nature Communications
Putting the “Tech” in Biotech: An Unconventional Path to Building a Therapeutics Company, with Federico Paoletti, PhD72 / 100
Accelerating Drug Development is a Moral Imperative with Dr. Gabi Hanna, MD
Biotech, Blockchain, and Building Companies with Russ Peloquin, Managing Partner of LifeSci Catalyst Partners
Funding, Partnerships, and Growth: Strategies for Startup Biotech Success with Fractional Chief Business Officer Renee Williams
The Science of Success: Transforming Scientific Concepts into Marketable Products with Stacy Frye, co-founder and CCO of Stimulus Bio